|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0022341,
umls-concept:C0024299,
umls-concept:C0055598,
umls-concept:C0079731,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0205219,
umls-concept:C0393022,
umls-concept:C0868928,
umls-concept:C0936012,
umls-concept:C1257890,
umls-concept:C1413947,
umls-concept:C1514923,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-3-18
|
|
pubmed:abstractText |
We performed a retrospective analysis of patients with diffuse large B cell lymphoma treated with rituximab plus CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) as a first-line therapy at 22 hospitals of the Kyushu Lymphoma Study Group. During the period 1996-2005, 1,057 patients (aged 22-90 years) were analyzed. Of these, 678 were treated with CHOP, and 379 were treated with rituximab plus CHOP (R-CHOP). The complete response rate was 59.9% in the CHOP group and 67.0% in the R-CHOP group (P < 0.001). Three-year progression-free survival (PFS) and overall survival (OS) rates were significantly higher in the R-CHOP group than in the CHOP group (61.3 vs. 45.6% for PFS, P < 0.001; 68.3 vs. 54.5% for OS, P < 0.001). The International Prognostic Index was a good prognostic marker for both groups; a survival benefit of rituximab addition was found for each risk subgroup and also for both age groups (<or=60 and >60 years). Among 345 patients who received localized radiation therapy, the adding rituximab to CHOP attenuated the survival difference between CHOP and R-CHOP groups (P = 0.104), compared with no radiation group (P < 0.001). Results of this large-scale, multicenter study confirm that rituximab plus CHOP provided a greater survival benefit than CHOP alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1865-3774
|
|
pubmed:author |
pubmed-author:AbeYasunobuY,
pubmed-author:EtoTetsuyaT,
pubmed-author:FujisakiTomoakiT,
pubmed-author:GondoHisashiH,
pubmed-author:HiguchiMasakazuM,
pubmed-author:ImamuraYutakaY,
pubmed-author:IwahashiMasahiroM,
pubmed-author:KamimuraTomohikoT,
pubmed-author:KawanoFumioF,
pubmed-author:MakinoShigeyoshiS,
pubmed-author:MatsumotoTadashiT,
pubmed-author:MoriuchiYukiyoshiY,
pubmed-author:NagafujiKojiK,
pubmed-author:OgawaRyosukeR,
pubmed-author:OhshimaKoichiK,
pubmed-author:OkamuraTakashiT,
pubmed-author:SekiRitsukoR,
pubmed-author:ShimodaKazuyaK,
pubmed-author:SuzukiKeikoK,
pubmed-author:SuzumiyaJunjiJ,
pubmed-author:SuzushimaHitoshiH,
pubmed-author:TaguchiFumihiroF,
pubmed-author:TamuraKazuoK,
pubmed-author:TsudaHiroyukiH,
pubmed-author:TsukazakiKunihiroK,
pubmed-author:UikeNaokuniN,
pubmed-author:UtsunomiyaAtaeA,
pubmed-author:YamashitaKiyoshiK,
pubmed-author:YoshidaMinoruM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
258-66
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20066574-Adult,
pubmed-meshheading:20066574-Antibodies, Monoclonal,
pubmed-meshheading:20066574-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20066574-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20066574-Combined Modality Therapy,
pubmed-meshheading:20066574-Cyclophosphamide,
pubmed-meshheading:20066574-Disease-Free Survival,
pubmed-meshheading:20066574-Doxorubicin,
pubmed-meshheading:20066574-Female,
pubmed-meshheading:20066574-Humans,
pubmed-meshheading:20066574-Japan,
pubmed-meshheading:20066574-Kaplan-Meier Estimate,
pubmed-meshheading:20066574-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:20066574-Male,
pubmed-meshheading:20066574-Middle Aged,
pubmed-meshheading:20066574-Multivariate Analysis,
pubmed-meshheading:20066574-Prednisone,
pubmed-meshheading:20066574-Proportional Hazards Models,
pubmed-meshheading:20066574-Retrospective Studies,
pubmed-meshheading:20066574-Survival Analysis,
pubmed-meshheading:20066574-Vincristine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
|
|
pubmed:publicationType |
Journal Article
|
